RegulatoryDEA files post-hearing brief recommending marijuana be moved to Schedule IIIRegulatoryGermany's medical cannabis insurance reform descends into regulatory disputeStudyPhase 3 trial of full-spectrum cannabis extract VER-01 for chronic low back pain published in Nature MedicineStudyUniversity of Sydney trial: cannabidiol significantly reduces chronic pain in people with nerve damageRegulatoryTGA responds to medicinal cannabis review, signalling overhaul of Australian access pathwaysBusinessFDA grants Breakthrough Therapy Designation to plant-derived cannabis extract for pain treatmentBusinessTilray expands cultivation capacity and updates guidance on German medical cannabis marketBusinessDunbar Pharma launches first plant-derived dronabinol in UK through IPS PharmaStudyAnanda Pharma's ENDOCAN study explores pharmaceutical-grade CBD for endometriosis careRegulatoryCongressional researchers note FDA has missed deadline to publish hemp cannabinoid lists and container guidanceRegulatoryDEA files post-hearing brief recommending marijuana be moved to Schedule IIIRegulatoryGermany's medical cannabis insurance reform descends into regulatory disputeStudyPhase 3 trial of full-spectrum cannabis extract VER-01 for chronic low back pain published in Nature MedicineStudyUniversity of Sydney trial: cannabidiol significantly reduces chronic pain in people with nerve damageRegulatoryTGA responds to medicinal cannabis review, signalling overhaul of Australian access pathwaysBusinessFDA grants Breakthrough Therapy Designation to plant-derived cannabis extract for pain treatmentBusinessTilray expands cultivation capacity and updates guidance on German medical cannabis marketBusinessDunbar Pharma launches first plant-derived dronabinol in UK through IPS PharmaStudyAnanda Pharma's ENDOCAN study explores pharmaceutical-grade CBD for endometriosis careRegulatoryCongressional researchers note FDA has missed deadline to publish hemp cannabinoid lists and container guidance
Institute for Cannabinoid Therapy emblem
Institute for Cannabinoid Therapy
Est. International Education
Courses
Module

The Antimicrobial Effects of Cannabinoids

Emerging science on the antibacterial and antimicrobial activity of cannabinoids and its clinical relevance.

Duration
40 minutes + quiz
Instructor
Daniel Gana
Level
Module
Enrolment
USD $100
Overview

This course is designed for healthcare professionals seeking a rigorous, evidence-based understanding of the antimicrobial effects of cannabinoids. It combines contemporary science, clinical reasoning and international regulatory perspective.

Learning objectives
  • Understand the scientific basis of the antimicrobial effects of cannabinoids.
  • Interpret the current clinical evidence and its limitations.
  • Apply the evidence responsibly within your regulatory framework.
Curriculum
  1. 01
    Recorded lecture

    A 40-minute lecture delivered by the module educator.

  2. 02
    Assessment quiz

    A short quiz confirming the key learning outcomes.

Who should attend
Medical practitionersNurse practitionersPharmacistsAllied healthResearchers
Frequently asked questions
Is this module part of a course?+

No — this is a standalone module, available for individual purchase at USD $100.

Are certificates provided?+

Yes — a certificate of completion is issued for each module.